FDA reviewers criticize Replimune drug; ProMIS climbs on Alzheimer’s data

RegulatoryNegative

AI Analysis

Summary

FDA reviewers issued criticism of Replimune's drug development, while ProMIS reported positive Alzheimer's disease data in a mixed set of regulatory updates for the biotech sector.

Outcome Details

FDA reviewers criticized Replimune drug

Importance:6/10

Sentiment:

-0.40

FDA reviewregulatory criticismAlzheimer's dataclinical development

Related Companies

$AVIR

Read the original article

Published by yahoo_finance on July 29, 2026 11:00 AM

Read Original